2025
May
Hidden gems: cryptic antigens as novel therapeutic targets in pancreatic cancer
May 21, 2025
Pancreatic ductal adenocarcinoma (PDAC) has proven resistant to immunotherapy strategies, in part due to limited tumor mutational burden and T cell infiltration. Besides tumor-specific somatic mutations resulting in neoantigens, cancer cells can also translate genome regions outside of annotated open reading frames (ORFs), resulting in HLA-I presentation of cryptic antigens derived from regions...
Hydrogelation preserves whole tumor cells for vaccination
May 14, 2025
Whole tumor vaccines are appealing as immunotherapies, as they contain the complete range of potential tumor antigens. However, tumor cell inactivation methods often degrade important tumor cell structures and antigens, and the immunogenicity of whole tumor cell vaccines is limited. To address these issues, Gao, Luo, Kwong, and Liu et al. developed an...
EPO acts as a tumor’s doping agent to evade immunosurveillance
May 7, 2025
While some biomarkers, such as low tumor mutational burden, have been associated with immune-cold tumors that respond poorly to immune checkpoint blockade (ICB), the mechanisms underlying the immunosuppressive tumor microenvironment (TME) remain largely unknown. Assessing this question, Chiu et al. recently published their findings on the influence of erythropoietin (EPO) in defining this...
